330 related articles for article (PubMed ID: 15383492)
1. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
Huang W; Lin YS; McConn DJ; Calamia JC; Totah RA; Isoherranen N; Glodowski M; Thummel KE
Drug Metab Dispos; 2004 Dec; 32(12):1434-45. PubMed ID: 15383492
[TBL] [Abstract][Full Text] [Related]
2. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
[TBL] [Abstract][Full Text] [Related]
3. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
[TBL] [Abstract][Full Text] [Related]
4. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.
Gorski JC; Hall SD; Jones DR; VandenBranden M; Wrighton SA
Biochem Pharmacol; 1994 Apr; 47(9):1643-53. PubMed ID: 8185679
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing midazolam hydroxylation activity in human liver microsomes.
He P; Court MH; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
[TBL] [Abstract][Full Text] [Related]
6. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.
Patki KC; Von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 2003 Jul; 31(7):938-44. PubMed ID: 12814972
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.
Gibbs MA; Thummel KE; Shen DD; Kunze KL
Drug Metab Dispos; 1999 Feb; 27(2):180-7. PubMed ID: 9929500
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes.
Dennison JB; Jones DR; Renbarger JL; Hall SD
J Pharmacol Exp Ther; 2007 May; 321(2):553-63. PubMed ID: 17272675
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5.
Bakken GV; Rudberg I; Christensen H; Molden E; Refsum H; Hermann M
Drug Metab Dispos; 2009 Feb; 37(2):254-8. PubMed ID: 19022943
[TBL] [Abstract][Full Text] [Related]
10. Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates.
Galetin A; Brown C; Hallifax D; Ito K; Houston JB
Drug Metab Dispos; 2004 Dec; 32(12):1411-20. PubMed ID: 15342470
[TBL] [Abstract][Full Text] [Related]
11. Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone.
Kamdem LK; Meineke I; Koch I; Zanger UM; Brockmöller J; Wojnowski L
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jul; 370(1):71-7. PubMed ID: 15232676
[TBL] [Abstract][Full Text] [Related]
12. Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b5 and inhibition by ketoconazole.
Michaud V; Simard C; Turgeon J
Drug Metab Lett; 2010 Apr; 4(2):95-103. PubMed ID: 21281268
[TBL] [Abstract][Full Text] [Related]
13. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
[TBL] [Abstract][Full Text] [Related]
14. Territrems B and C metabolism in human liver microsomes: major role of CYP3A4 and CYP3A5.
Peng FC; Chang CC; Yang CY; Edwards RJ; Doehmer J
Toxicology; 2006 Feb; 218(2-3):172-85. PubMed ID: 16337070
[TBL] [Abstract][Full Text] [Related]
15. Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide).
Tseng E; Walsky RL; Luzietti RA; Harris JJ; Kosa RE; Goosen TC; Zientek MA; Obach RS
Drug Metab Dispos; 2014 Jul; 42(7):1163-73. PubMed ID: 24737844
[TBL] [Abstract][Full Text] [Related]
16. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.
Walsky RL; Obach RS; Hyland R; Kang P; Zhou S; West M; Geoghegan KF; Helal CJ; Walker GS; Goosen TC; Zientek MA
Drug Metab Dispos; 2012 Sep; 40(9):1686-97. PubMed ID: 22645092
[TBL] [Abstract][Full Text] [Related]
17. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
Ramírez J; Innocenti F; Schuetz EG; Flockhart DA; Relling MV; Santucci R; Ratain MJ
Drug Metab Dispos; 2004 Sep; 32(9):930-6. PubMed ID: 15319333
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of testosterone 6beta-hydroxylation in the reconstituted system with similar ratios of purified CYP3A4, NADPH-cytochrome p450 oxidoreductase and cytochrome B5 to human liver microsomes.
Taguchi M; Imaoka S; Yoshii K; Kobayashi K; Hosokawa M; Shimada N; Funae Y; Chiba K
Res Commun Mol Pathol Pharmacol; 2001 Jul; 109(1-2):53-63. PubMed ID: 11458985
[TBL] [Abstract][Full Text] [Related]
19. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.
Hesse LM; Venkatakrishnan K; von Moltke LL; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2001 Feb; 29(2):133-40. PubMed ID: 11159802
[TBL] [Abstract][Full Text] [Related]
20. Significance of the minor cytochrome P450 3A isoforms.
Daly AK
Clin Pharmacokinet; 2006; 45(1):13-31. PubMed ID: 16430309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]